Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations.
Patil T, Gao D, Watson A, Sakamoto M, Nie Y, Gibson A, Dean ML, Yoder BA, Miller E, Stalker M, Aisner DL, Bunn PA, Schenk EL, Marmarelis ME, Bennati C, Navani V, Zhang Y, Camidge DR. Patil T, et al. Among authors: aisner dl. Lung Cancer. 2024 Nov 25;199:108040. doi: 10.1016/j.lungcan.2024.108040. Online ahead of print. Lung Cancer. 2024. PMID: 39615411 Free article.
Current clinical practices and challenges in molecular testing: a GOAL Consortium Hematopathology Working Group report.
Lee TD, Aisner DL, David MP, Eno CC, Gagan J, Gocke CD, Guseva NV, Haley L, Jajosky AN, Jones D, Mansukhani MM, Mroz P, Murray SS, Newsom KJ, Paulson V, Roy S, Rushton C, Segal JP, Senaratne TN, Siddon AJ, Starostik P, Van Ziffle JAG, Wu D, Xian RR, Yohe S, Kim AS. Lee TD, et al. Among authors: aisner dl. Blood Adv. 2023 Aug 22;7(16):4599-4607. doi: 10.1182/bloodadvances.2023010149. Blood Adv. 2023. PMID: 37236162 Free PMC article.
Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC.
Tompkins W, Grady CB, Hwang WT, Chandrasekhara K, McCoach C, Sun F, Liu G, Patel D, Nieva J, Herrmann A, Marrone K, Lam VK, Velcheti V, Liu SV, Montenegro GLB, Patil T, Weiss J, Miller KL, Schwartzman W, Dowell JE, Shaverdashvili K, Villaruz L, Cass A, Iams W, Aisner D, Aggarwal C, Camidge DR, Marmarelis ME, Sun L. Tompkins W, et al. JTO Clin Res Rep. 2024 Mar 26;5(8):100669. doi: 10.1016/j.jtocrr.2024.100669. eCollection 2024 Aug. JTO Clin Res Rep. 2024. PMID: 39157674 Free PMC article.
Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator's Consortium Registry Analysis.
Stalker M, Grady CB, Watts A, Hwang WT, Chandrasekhara K, Sun F, Liu G, Patel D, Nieva J, Herrmann A, Marrone K, Lam VK, Velcheti V, Liu SV, Bravo Montenegro GL, Tompkins W, Patil T, Weiss J, Miller KL, Schwartzman W, Dowell JE, Shaverdashvili K, Villaruz L, Cass A, Iams W, Aisner D, Aggarwal C, Camidge DR, Sun L, Marmarelis ME. Stalker M, et al. JTO Clin Res Rep. 2024 Nov 12;6(1):100765. doi: 10.1016/j.jtocrr.2024.100765. eCollection 2025 Jan. JTO Clin Res Rep. 2024. PMID: 39758601 Free PMC article.
The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC.
Patil T, Staley A, Nie Y, Sakamoto M, Stalker M, Jurica JM, Koehler K, Cass A, Kuykendall H, Schmitt E, Filar E, Reventaite E, Davies KD, Nijmeh H, Haag M, Yoder BA, Bunn PA, Schenk EL, Aisner DL, Iams WT, Marmarelis ME, Camidge DR. Patil T, et al. Among authors: aisner dl. JTO Clin Res Rep. 2024 Jan 18;5(2):100637. doi: 10.1016/j.jtocrr.2024.100637. eCollection 2024 Feb. JTO Clin Res Rep. 2024. PMID: 38361741 Free PMC article.
A Case of Fetal-Induced Graft-versus-Host Disease.
Schreiber AR, Santos J, McMahon B, Buckner TW, Olson C, Alberti MO, Guimarães-Young A, Knoeckel C, Broussard L, Aubrey M, Palmer BE, Weiss E, Connors GR, Brunner S, Wisell JA, Pacheco T, Aisner DL, Gutman JA. Schreiber AR, et al. Among authors: aisner dl. N Engl J Med. 2023 Aug 17;389(7):668-670. doi: 10.1056/NEJMc2307669. N Engl J Med. 2023. PMID: 37585636 No abstract available.
Clinical and Radiographic Benefit of a Patient With Metastatic Non-Small Cell Lung Cancer Harboring an EGFR::ERBB4 Fusion Through Use of EGFR Tyrosine Kinase Inhibitors.
Guimaraes-Young A, Davies KD, Trevisan P, Nijmeh H, Haag M, Aisner DL, Patil T. Guimaraes-Young A, et al. Among authors: aisner dl. JCO Precis Oncol. 2024 Dec;8:e2400526. doi: 10.1200/PO-24-00526. Epub 2024 Dec 5. JCO Precis Oncol. 2024. PMID: 39637337 Free PMC article. No abstract available.
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
Blakely CM, Urisman A, Gubens MA, Mulvey CK, Allen GM, Shiboski SC, Rotow JK, Chakrabarti T, Kerr DL, Aredo JV, Bacaltos B, Gee M, Tan L, Jones KD, Devine WP, Doebele RC, Aisner DL, Patil T, Schenk EL, Bivona TG, Riess JW, Coleman M, Kratz JR, Jablons DM. Blakely CM, et al. Among authors: aisner dl. J Clin Oncol. 2024 Sep 10;42(26):3105-3114. doi: 10.1200/JCO.24.00071. Epub 2024 Jul 19. J Clin Oncol. 2024. PMID: 39028931 Free PMC article. Clinical Trial.
134 results